Gentium Presented Laboratory Data at XXth Congress of International Society for Thrombosis and Haemostasis; Laboratory Data Pres

Gentium S.p.A. (AMEX: GNT) (the "Company") announced
that earlier today in Sydney, Australia, Dr. Guenther Eissner, Ph.D,
Chief of the Molecular Biology Research Laboratory for Gentium,
presided over a poster presentation at the XXth Annual Congress of the
International Society on Thrombosis and Hemostasis. The poster
presentation, "Defibrotide and Oligotide, Two DNA-Based Drugs, Protect
Human Microvascular Endothelial Cells Against Chemotherapy-Induced
Damage and Activation," reports that data showed the drugs' potential
ability to protect human endothelial cells from chemotherapy-induced
activation, transendothelial migration and apoptotic damage and may
eliminate the increased allogenicity of cytotoxic T cells (CTL). In
laboratory studies Defibrotide showed anti-thrombotic, anti-ischemic,
and pro-fibrinolytic activity with endothelium protective effects.
   Defibrotide, the company's lead product candidate in the U.S., is
an investigational drug that has been granted Orphan Drug status by
the U.S. FDA to treat veno-occlusive disease (VOD) with multiple organ
failure ("Severe VOD") and Fast Track designation to facilitate
development and expedite the agency's review of the drug.
   Dr. Massimo Iacobelli, Gentium's scientific director, commented on
the outcome of the study, "This is very encouraging data as to the
effects of conditioning with Defibrotide and Oligotide prior to
allogeneic stem cell transplantation and cancer chemotherapy of solid
tumors, where in both cases, the stabilization of the vascular
endothelium is one of the pivotal steps to cure."

   About VOD

   Severe VOD is a potentially life-threatening condition in which
some of the veins in the liver are blocked as a result of toxic cancer
treatments such as chemotherapy, radiation, hormone therapy and bone
marrow and stem cell transplants. It is estimated that 80% of patients
with Severe VOD die with 100 days. There are no currently approved
treatments for Severe VOD.

   About the Company

   Gentium S.p.A. is a biopharmaceutical company located in Villa
Guardia (Como), Italy that is focused on the research, discovery and
development of drugs derived from DNA extracted from natural sources
and drugs which are synthetic oligonucleotides (molecules chemically
similar to natural DNA) to treat and prevent a variety of vascular
diseases and conditions related to cancer and cancer treatments.

   Cautionary Note Regarding Forward-Looking Statements

   This press release contains "forward-looking statements." In some
cases, you can identify these statements by forward-looking words such
as "may," "might," "will," "should," "expect," "plan," "anticipate,"
"believe," "estimate," "predict," "potential" or "continue," the
negative of these terms and other comparable terminology. These
statements are not historical facts but instead represent the
Company's belief regarding future results, many of which, by their
nature, are inherently uncertain and outside the Company's control. It
is possible that actual results may differ, possibly materially, from
those anticipated in these forward-looking statements. For a
discussion of some of the risks and important factors that could
affect future results, see the discussion in our Prospectus filed with
the Securities and Exchange Commission under Rule 424(b)(4) under the
caption "Risk Factors."